Advertisement

Ariad Pharmaceuticals Inc. reported initial clinical results for its drug for advanced acute myeloid leukemia (AML), and is now planning the next steps to clinically develop ponatinib.

The Phase 1 study covered 12 patients with relapsed or refractory AML. It showed the potential benefit of ponatinib in AML patients with the FLT3 mutation. Three out of seven (43 percent) patients who had no prior treatment with investigational FLT3 inhibitors had clinical and hematologic evidence of anti-leukemic activity (two complete responses with incomplete blood count recovery and one partial response), which corresponds to three out of 12 patients overall (25 percent).

SOURCE

Advertisement
Advertisement